Finland· FI-EU-EU/1/97/033/002
Avonex
A interferon beta-1a product, registered in Finland by Biogen Netherlands B.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Interferon beta-1a is registered in 14 of 19 countries.
Countries holding a registration under ATC L03AB07 (interferon beta-1a), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 9 of them publish a price we can compare per daily dose
Interferon beta-1a · ATC L03AB07
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of interferon beta-1a costs, country by country.
Normalised to the WHO defined daily dose (4.3 mcg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Interferon beta-1a · price per daily dose (4.3 mcg)
USD · FX 28 Sept 2026
- CH Switzerland$13.13
The record
At a glance
Fimea (Finland)- Manufacturer
- Biogen Netherlands B.V.
- Country
- Finland (FI)
- ATC code
- L03AB07
- ATC class
- Interferon beta-1a
- Defined daily dose
- 4.3 mcg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- June 4, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
347 interactions on record for interferon beta-1a.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Interferon beta-1a · interactions on record
347 records
- 15 severe
- 332 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- ZidovudineJ05AF01severe
- ClotrimazoleA01AB18moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L03AB07
Interferon beta-1a, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ca391971-cac2-4db5-9fe8-48dfa6833c34 GET /v1/drugs/ca391971-cac2-4db5-9fe8-48dfa6833c34?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "4.3",
"form": "injektiokuiva-aine ja liuotin, liuosta varten",
"route": null,
"ddd_unit": "mcg",
"strength": "30 mikrog",
"atc_label": "interferoni beeta-1a",
"ma_number": null,
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": "EU/1/97/033/002",
"fimea_rel_id": "REL4199",
"authorised_at": "1997-03-13"
}See everything about interferon beta-1a.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.